Therapeutic carbamazepine (CBZ) and valproic acid (VPA) monitoring in children using saliva as a biologic fluid

Journal of Epilepsy and Clinical Neurophysiology

Volumn 14, Issue 2, 2008, Pages 55-58

  Maldonado, C ^a,b   Fagiolino, Pietro ^a,b   Vazquez M ^a,b   Rey, A ^a,c   Olano, I ^a,b   Eiraldi, R ^a,b   Scavone, C ^a,c  

^a UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^b University Hospital   (Uruguay)

^c Faculty of Medicine   (France)

Author keywords

Carbamazepine; Efflux transporters; Refractory epilepsy; Saliva concentration; Valproic acid

Indexed keywords

CARBAMAZEPINE; CITRIC ACID; VALPROIC ACID;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG MONITORING; DRUG SALIVA LEVEL; EPILEPSY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; PATIENT MONITORING; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SALIVA; SCHOOL CHILD;

EID: 70549113655     PISSN: 16762649     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1676-26492008000200003     Document Type: Article

References (12)

1. Fagiolino P, Vázquez M, Olano I, Delfino A. Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. J Epilepsy Clin Neurophysiol. 2006; 12:13-16 (Pubitemid 47256984)
2. Sundqvist A, Tomson T, Lundkvist B. Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy. Ther Drug Monit 1997; 19:153-159 (Pubitemid 28056025)
3. th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology Abstract. Ther Drug Monit 2007; 29:535.
4. Lazarowski A, Czomyj L, Lubieniecki F, Vázquez S, D'Giano C, Sevlever G, Taratuto AL, Brusco A, Girardi E. Multidrug-resistance (MDR) proteins develops refractory epilepsy phenotype: clinical and experimental evidences. Current Drug Therapy 2006; 1:291-309.
5. Haidukewych D, Zielinski JJ, Rodin EA. Derivation and evaluation for prediction of free carbamazepine concentration in patients comedicated with valproic acid. Ther Drug Monit 1989; 11:528-532 (Pubitemid 19232947)
6. May T, Rambeck B. Serum concentration of valproic acid: influence of dose and comedication. Ther Drug Monit 1985; 7:387-390 (Pubitemid 16198523)
7. Yukawa E, Honda T, Ohdo S, Higuchi S, Aoyama T. Detection of carbamazepine-induced changes in valproic acid relative clearance in man by simple pharmacokinetic screening. J Pharm Pharmacol 1997; 49:751-756 (Pubitemid 27386894)
8. Hoffmann K, Gastens AM, Volk HA, Löscher W. Expression of the multidrug transporter MRP2 in the blood-brain barrier after pilocarpine-induced seizures in rats. Epilepsy Res 2006; 69:1-14.
9. Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005; 2:86-98. (Pubitemid 40128029)
10. Uematsu T, Yamaoka M, Matsuura T, Doto R, Hotomi H, Yamada A, Hasumi-Nakayama Y, Kayamoto D. P-glycoprotein expression in human major and minor salivary glands. Arch Oral Biol 2001; 46:521-527 (Pubitemid 32476082)
11. Drozdzik M, Mysliwiec K, Lewinska-Chelstowska M, Banach J, Drozdzik A, Grabarek J. P-glycoprotein drug transporter MDR1 gene polymorphism in renal transplant patients with and without gingival overgrowth. J Clin Periodontol 2004; 31:758-763 (Pubitemid 39186430)
12. Shiran MR, Hassanzadeh-Khayyat M, Iqbal MZ, Lagundoye O, Seivewright N, Lennard MS, Tucker GT, Rostami-Hodjegan A. Can saliva replace plasma for the monitoring of methadone? Ther Drug Monit 2005; 27:580-586